Market Place
Sourcing Support
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract
25 Oct 2023 //
PR NEWSWIRE
CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus
16 Oct 2023 //
PR NEWSWIRE
CANbridge Announces Enrollment Reached in Core Part of The CAN103 Phase 2 Trial
16 Oct 2023 //
PR NEWSWIRE
CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan
08 Oct 2023 //
PR NEWSWIRE
CANbridge to Participate in Two Investor Conferences in September
06 Sep 2023 //
PR NEWSWIRE
CANbridge Announces Interim Financial Results and Corporate Updates
31 Aug 2023 //
PR NEWSWIRE
CANbridge to Continue CAN008 Phase 2 Trial in GBM in China
03 Jul 2023 //
BUSINESSWIRE
CANbridge Reports Positive Preliminary Data in the Omoprubart Phase 1b Trial
26 Jun 2023 //
BUSINESSWIRE
CANbridge Reports +ve Preliminary Data in the Omoprubart Ph1b Trial PNH in China
26 Jun 2023 //
BUSINESSWIRE
CANbridge Announces Marketing Approval of CAN108 in China
02 Jun 2023 //
BUSINESSWIRE
CANbridge Announces Full Enrollment Reached in China Region of Global LIVMARLI
30 May 2023 //
BUSINESSWIRE
CANbridge and CAN203 Improves Lifespan and Motor Function
17 May 2023 //
BUSINESSWIRE
CANbridge Pharmaceuticals Appoints Jason West VP, Head of Gene Therapy
04 May 2023 //
BUSINESSWIRE
CANbridge-UMass Chan Medical School SMA Gene Therapy Data ASGCT
02 May 2023 //
BUSINESSWIRE
CANbridge Announces Financial Results for December 31, 2022
30 Mar 2023 //
BUSINESSWIRE
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of GBM
27 Mar 2023 //
BUSINESSWIRE
Data from CANbridge CAN008 Ph1/2 Trial in Shows 67% Five-Year Survival Rate
16 Mar 2023 //
BUSINESSWIRE
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial
18 Jan 2023 //
BUSINESSWIRE
CANbridge Pharmaceuticals Granted Orphan Drug Designation for CAN 106
15 Nov 2022 //
BUSINESSWIRE
CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI
26 Oct 2022 //
BUSINESSWIRE
CANbridge Chan Medical School Gene Therapy Research in Presentation at ESGCT
13 Oct 2022 //
BUSINESSWIRE
CANbridge Pharmaceuticals to Participate in Upcoming Investor Conferences
12 Oct 2022 //
BUSINESSWIRE
CANbridge Pharmaceuticals Data on CAN106 to be Presented at Two Conferences
23 Sep 2022 //
BUSINESSWIRE
CANbridge Pharma to Participate in Two Investor Conferences in September
12 Sep 2022 //
BUSINESSWIRE
CANbridge Announces Financial Results for Six Months Ended June 30, 2022
24 Aug 2022 //
BUSINESSWIRE
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial
20 Jul 2022 //
BUSINESSWIRE
First Patient Dosed in CAN108 EMBARK PII Study in Biliary Atresia in China
14 Jul 2022 //
BIOSPACE
CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106
06 Jul 2022 //
BUSINESSWIRE
CANbridge Appoints Industry Leader Edward Hu to the Board
05 Jul 2022 //
BUSINESSWIRE
CANbridge CAN106 PI Data Presented at the EHA 2022 Congress
10 Jun 2022 //
BUSINESSWIRE
CANbridge Pharma to Present at Jefferies Global Healthcare Conference 2022
01 Jun 2022 //
BUSINESSWIRE
CANbridge to Participate in the Morgan Stanley Virtual China Summit 2022
20 May 2022 //
BIOSPACE
CANbridge-UMass Chan Medical School Gene Therapy Research Presented at ASGCT
16 May 2022 //
BUSINESSWIRE
CANbridge to Present CAN106 PI Data at the EHA 2022 Congress
12 May 2022 //
BUSINESSWIRE
CANbridge Appoints Pauline Li as Senior VP of Clinical Development & Operations
11 May 2022 //
BUSINESSWIRE
CANbridge-UMass Chan MSG Therapy Research to be Presented at ASCGT
03 May 2022 //
BUSINESSWIRE
CANbridge Pharma`s CAN108 NDA/ORD for Alagille Syndrome Accepted by Taiwan FDA
28 Mar 2022 //
BUSINESSWIRE
First Patient Dosed in CAN106 Phase 1b/2 Trial for PNH
27 Mar 2022 //
BUSINESSWIRE
CANbridge Announces Financial Results and Corporate Updates
22 Mar 2022 //
BUSINESSWIRE
CANbridge Bags Approval of CAN108 for Rare Liver Disease, Alagille Syndrome
25 Feb 2022 //
BUSINESSWIRE
CANbridge Pharmaceuticals Appoints Dr. Lan Hu as New Independent Director
16 Feb 2022 //
BUSINESSWIRE
CANbridge Reports Positive Top-Line CAN106 Phase 1 Data
07 Feb 2022 //
BUSINESSWIRE
CANbridge Pharmaceuticals` CAN108 NDA for Alagille Syndrome Accepted by NMPA
18 Jan 2022 //
BUSINESSWIRE
CANbridge gets Hong Kong IPO as Nasdaq slowdown prompts renewed market analysis
13 Dec 2021 //
ENDPTS
Qiming`s Portfolio Company CANbridge Pharmaceuticals Lists on Main Board of HKEx
09 Dec 2021 //
ASIAONE
CANbridge Signs Collaboration Agreement with the Peking Union Medical College
09 Dec 2021 //
BUSINESSWIRE
US-China ink gene therapy research agreement for Duchenne Muscular Dystrophy
04 Nov 2021 //
BIOSPECTRUMASIA
Pfizer appeals on anti-kickback case; and more
01 Nov 2021 //
ENDPTS
CANbridge Begins Dosing for CAN008 Phase 2 Trial in GBM in China
26 Oct 2021 //
BUSINESSWIRE
CANbridge Enters into WW Research Collaboration with Scriptr Global
25 Oct 2021 //
BUSINESSWIRE
CANbridge Pharma CAN103 Investigational New Drug Application Approved in China
20 Oct 2021 //
BUSINESSWIRE
FDA Action Alert: Mirum and Kite/Gilead
27 Sep 2021 //
BIOSPACE
CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted
02 Aug 2021 //
BUSINESS WIRE
CANbridge`s CAN106 Investigational New Drug Application Approved in China
15 Jul 2021 //
BUSINESS WIRE
CANbridge Announces Strategic Collaboration with LogicBio Therapeutics
27 Apr 2021 //
BUSINESSWIRE
First Subject Dosed in CANbridge Pharmaceuticals CAN106 Trial
09 Mar 2021 //
BUSINESSWIRE
First Subject Dosed in CANbridge Pharmaceuticals CAN106 Trial
09 Mar 2021 //
BUSINESSWIRE
CANbridge & Puma Agree to Terminate NERLYNX® License Agreement
26 Feb 2021 //
BUSINESSWIRE
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX®
25 Feb 2021 //
BUSINESSWIRE
